Sangamo Therapeutics Inc
SGMO0.460USD
+0.014+3.09%
Close 12/22, 16:00（ET）Quotes delayed by 15 min
148.19MMarket Cap
LossP/E TTM
More Details of Sangamo Therapeutics Inc Company
Sangamo Therapeutics, Inc. is a genomic medicine company. The Company’s zinc finger (ZF) epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid engineering platform has demonstrated the ability to expand delivery beyond available intrathecal delivery capsids, including in the central nervous system (CNS), in preclinical studies. Zinc finger technologies are derived from naturally occurring human proteins. They are composed of a DNA-binding domain, which binds with precision to any sequence of DNA, and various functional domains (such as nucleases and transcription factors) based on therapeutic needs. Its pipeline includes Chronic Neuropathic Pain - ST-503 and Isaralgagene civaparvovec (ST-920). ST-503 is an investigational epigenetic regulator for the treatment of intractable pain due to iSFN, a type of chronic neuropathic pain. ST-920 is a wholly owned gene therapy product candidate for the treatment of Fabry disease.
Sangamo Therapeutics Inc Info
Ticker SymbolSGMO
Company nameSangamo Therapeutics Inc
IPO dateApr 06, 2000
CEOMacrae (Alexander D)
Number of employees183
Security typeOrdinary Share
Fiscal year-endApr 06
Address501 Canal Blvd.
CityRICHMOND
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94084
Phone15109706000
Websitehttps://www.sangamo.com/
Ticker SymbolSGMO
IPO dateApr 06, 2000
CEOMacrae (Alexander D)
Company Executives of Sangamo Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Scott B. Willoughby
Mr. Scott B. Willoughby
Chief Legal Officer & Corporate Secretary
Chief Legal Officer & Corporate Secretary
302.87K
-0.67%
Dr. Gregory Davis, Ph.D.
Dr. Gregory Davis, Ph.D.
Head of Research & Technology
Head of Research & Technology
197.63K
-0.36%
Ms. Margaret A. Horn, J.D.
Ms. Margaret A. Horn, J.D.
Independent Director
Independent Director
76.40K
+48.64%
Dr. Courtney Beers, Ph.D.
Dr. Courtney Beers, Ph.D.
Independent Director
Independent Director
76.40K
+48.64%
Dr. Karen Lesley Smith, M.D., Ph.D.
Dr. Karen Lesley Smith, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. John H. Markels, Ph.D.
Dr. John H. Markels, Ph.D.
Independent Director
Independent Director
--
--
Ms. Louise Wilkie
Ms. Louise Wilkie
Investor Relations
Investor Relations
--
--
Ms. H. Stewart Parker
Ms. H. Stewart Parker
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Nathalie Dubois- Stringfellow, Ph.D.
Ms. Nathalie Dubois- Stringfellow, Ph.D.
Chief Development Officer
Chief Development Officer
--
--
Mr. Robert F. Carey
Mr. Robert F. Carey
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Scott B. Willoughby
Mr. Scott B. Willoughby
Chief Legal Officer & Corporate Secretary
Chief Legal Officer & Corporate Secretary
302.87K
-0.67%
Dr. Gregory Davis, Ph.D.
Dr. Gregory Davis, Ph.D.
Head of Research & Technology
Head of Research & Technology
197.63K
-0.36%
Ms. Margaret A. Horn, J.D.
Ms. Margaret A. Horn, J.D.
Independent Director
Independent Director
76.40K
+48.64%
Dr. Courtney Beers, Ph.D.
Dr. Courtney Beers, Ph.D.
Independent Director
Independent Director
76.40K
+48.64%
Dr. Karen Lesley Smith, M.D., Ph.D.
Dr. Karen Lesley Smith, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. John H. Markels, Ph.D.
Dr. John H. Markels, Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
FY2024
FY2023
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
57.80M
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Fri, Nov 21
Updated: Fri, Nov 21
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
3.45%
Renaissance Technologies LLC
3.03%
Two Sigma Investments, LP
1.38%
BlackRock Institutional Trust Company, N.A.
1.35%
GSA Capital Partners LLP
1.09%
Other
89.70%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
3.45%
Renaissance Technologies LLC
3.03%
Two Sigma Investments, LP
1.38%
BlackRock Institutional Trust Company, N.A.
1.35%
GSA Capital Partners LLP
1.09%
Other
89.70%
Shareholder Types
Shareholders
Proportion
Investment Advisor
8.22%
Hedge Fund
6.55%
Investment Advisor/Hedge Fund
2.89%
Research Firm
1.04%
Corporation
0.97%
Individual Investor
0.95%
Other
79.37%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
319
55.42M
16.47%
-39.56M
2025Q2
349
61.18M
25.54%
-60.51M
2025Q1
404
58.78M
24.86%
-65.68M
2024Q4
408
67.57M
32.39%
-54.70M
2024Q3
411
61.90M
29.72%
-75.37M
2024Q2
422
105.29M
52.02%
-52.38M
2024Q1
424
122.66M
61.96%
-20.13M
2023Q4
430
104.60M
58.76%
-36.84M
2023Q3
436
126.62M
71.56%
-23.29M
2023Q2
448
137.28M
80.06%
-15.05M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
9.37M
3.11%
--
--
Jun 30, 2025
Renaissance Technologies LLC
6.84M
2.27%
+3.67M
+115.88%
Jun 30, 2025
Two Sigma Investments, LP
2.08M
0.69%
+397.81K
+23.60%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
4.18M
1.38%
-371.02K
-8.16%
Jun 30, 2025
GSA Capital Partners LLP
2.25M
0.74%
+1.28M
+132.40%
Jun 30, 2025
Geode Capital Management, L.L.C.
2.33M
0.77%
+48.83K
+2.14%
Jun 30, 2025
Biogen Inc
3.25M
1.08%
-11.40M
-77.82%
Aug 14, 2024
Susquehanna International Group, LLP
773.27K
0.26%
-1.04M
-57.27%
Jun 30, 2025
Charles Schwab Investment Management, Inc.
1.28M
0.42%
+183.97K
+16.76%
Jun 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
Invesco NASDAQ Future Gen 200 ETF
0.62%
iShares Neuroscience and Healthcare ETF
0.28%
Global X Genomics & Biotechnology ETF
0.2%
Invesco RAFI US 1500 Small-Mid ETF
0.02%
iShares Micro-Cap ETF
0%
ProShares Hedge Replication ETF
0%
Schwab U.S. Small-Cap ETF
0%
State Street SPDR S&P Kensho New Econ Comp ETF
0%
State Street SPDR S&P Biotech ETF
0%
Global X Russell 2000 Covered Call ETF
0%
View more
Invesco NASDAQ Future Gen 200 ETF
Proportion0.62%
iShares Neuroscience and Healthcare ETF
Proportion0.28%
Global X Genomics & Biotechnology ETF
Proportion0.2%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.02%
iShares Micro-Cap ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
Schwab U.S. Small-Cap ETF
Proportion0%
State Street SPDR S&P Kensho New Econ Comp ETF
Proportion0%
State Street SPDR S&P Biotech ETF
Proportion0%
Global X Russell 2000 Covered Call ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Sangamo Therapeutics Inc?
The top five shareholders of Sangamo Therapeutics Inc are:
The Vanguard Group, Inc. holds 9.37M shares, accounting for 3.11% of the total shares.
Renaissance Technologies LLC holds 6.84M shares, accounting for 2.27% of the total shares.
Two Sigma Investments, LP holds 2.08M shares, accounting for 0.69% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 4.18M shares, accounting for 1.38% of the total shares.
GSA Capital Partners LLP holds 2.25M shares, accounting for 0.74% of the total shares.
The Vanguard Group, Inc. holds 9.37M shares, accounting for 3.11% of the total shares.
Renaissance Technologies LLC holds 6.84M shares, accounting for 2.27% of the total shares.
Two Sigma Investments, LP holds 2.08M shares, accounting for 0.69% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 4.18M shares, accounting for 1.38% of the total shares.
GSA Capital Partners LLP holds 2.25M shares, accounting for 0.74% of the total shares.
What are the top three shareholder types of Sangamo Therapeutics Inc?
The top three shareholder types of Sangamo Therapeutics Inc are:
The Vanguard Group, Inc.
Renaissance Technologies LLC
Two Sigma Investments, LP
The Vanguard Group, Inc.
Renaissance Technologies LLC
Two Sigma Investments, LP
How many institutions hold shares of Sangamo Therapeutics Inc (SGMO)?
As of 2025Q3, 319 institutions hold shares of Sangamo Therapeutics Inc, with a combined market value of approximately 55.42M, accounting for 16.47% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -9.07%.
What is the biggest source of revenue for Sangamo Therapeutics Inc?
In FY2024, the -- business generated the highest revenue for Sangamo Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
